Novartis Hopes For Canakinumab In Lung Cancer Nosedive
Second Phase III Fail In NSCLC
Executive Summary
After deciding to examine canakinumab's potential in lung cancer on the back of the CANTOS cardiovascular trial, Novartis designed a major late-stage program in oncology for the interleukin-1 beta inhibitor. The second of those CANOPY trials has just come crashing down.
You may also be interested in...
Novartis's Tislelizumab Takes First Step On US Approval Path
Novartis has filed the PD-1 inhibitor tislelizumab, licensed from BeiGene, for second-line esophageal cancer with the FDA, the first submission outside China for the closely-watched therapy.
Wider Than AZ’s PACIFIC – Novartis Has Broad NSCLC Plans For Canakinumab
Novartis is taking its unexpected CANTOS cancer findings for canakinumab and running with them to Phase III in an adjuvant lung cancer setting that is broader that AstraZeneca's PACIFIC study.
CANTOS: Modest CV And Intriguing Lung Cancer Benefit With Canakinumab
With CANTOS, Novartis's canakinumab has become the first investigational treatment to show that selectively targeting inflammation significantly reduces cardiovascular risk, albeit modestly, but with the added bonus of reducing lung cancer.